Answers are grounded in this paper and cite their sources.
Trials assessing dupilumab in atopic dermatitis (AD) showed transient eosinophilia in less than 2% of patients (1). The frequency of hypereosinophilia (HE), defined as eosinophil blood count (EBC) ≥1500/mm3 (2), was higher (15.8%) in our previous real-life cohort of AD patients treated with dupilumab (3). Since symptomatic HE was reported in asthma trials, we aimed to assess the clinical impact of HE in AD patients receiving dupilumab.
No takes yet. Share an insight, caveat, or question.
Marcant et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: